American Journal of BioMedicine Volume 1, Issue 2, pages 58-72, December 2013
References
1. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM; West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357: 1477–86. [PubMed]
2. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310–19. [PubMed]
3. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320–8. [PubMed]
4. Finne P, Stenman UH, Määttänen L, Mäkinen T, Tammela TL, Martikainen P, Ruutu M, et al. The Finnish trial of prostate cancer screening: where are we now? BJU Int 2003; 92: 22–6. [Full Article (HTML)]
5. Wu K. Hu FB, Willett WC, Giovannucci E. Dietary patterns and risk of prostate cancer in U.S. men. Cancer Epidemiol Biomarkers Prev 2006; 15: 167–71. [PubMed]
6. Murtola TJ, Tammela TLJ, Lahtela J, Auvinen A. Serum lipid-lowering drugs and prostate cancer risk—a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007; 16: 2226–32. [PubMed]
7. Whitaker M, Hruby G, Lovett A, Patanjali N. Prostate HDR brachytherapy catheter displacement between planning and treatment delivery. Radiother Oncol. 2011;101(3):490-4. [PubMed]
8. Egawa S, Shimura S, Irie A, et al. Toxicity and health-related quality of life during and after high dose rate brachytherapy followed by external beam radiotherapy for prostate cancer. Jpn J Clin Oncol 2001;31:541–547. [PubMed]
9. Ishiyama H, Kitano M, Satoh T, et al. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity. Int J Radiat Oncol Biol Phys 2009;75:23–28. [PubMed]
10. Whitaker M, Hruby G, Lovett A, et al. Prostate HDR brachytherapy catheter displacement between planning and treatment delivery. Radiother Oncol 2011;101:490–494. [PubMed]
11. Tiong A, Bydder S, Ebert M, et al. A small tolerance for catheter displacement in high-dose rate prostate brachytherapy is necessary and feasible. Int J Radiat Oncol Biol Phys 2010;76:1066–1072. [PubMed]
12. Herrmann MK, Kertesz T, Gsänger T, et al. Gold marker displacement due to needle insertion during HDR brachytherapy for treatment of prostate cancer: a prospective cone beam computed tomography and kilovoltage on-board imaging (kV-OBI) study. Radiat Oncol 2012;7:24. [PubMed]
13. Tejwani A, Bieniek E, Puckett L, et al. Case series analysis of post-brachytherapy prostate edema and its relevance to post-implant dosimetry. Post-implant prostate edema and dosimetry. J Contemp Brachytherapy 2012;4:75–80. [PubMed]
14. Kolkman-Deurloo IK, Roos MA, Aluwini S. HDR monotherapy for prostate cancer: A simulation study to determine the effect of catheter displacement on target coverage and normal tissue irradiation. Radiother Oncol 2011;98:192–197. [PubMed]
15. Sullivan L, Williams SG, Tai KH, et al. Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiother Oncol 2009;91:232–236. [PubMed]
16. Zu K, Giovannucci E. Smoking and aggressive prostate cancer: a review of the epidemiologic evidence. Cancer Causes Control 2009; 20(10):1799-1810. [PubMed]
17. Daniell HW. A worse prognosis for smokers with prostate cancer. J Urol 1995;154(1):153-157. [PubMed]
18. Moreira DM, Antonelli JA, Presti JC Jr, et al. Association of cigarette smoking with interval to biochemical recurrence after radical prostatectomy. Urology 2010;76(5):1218-1223. [PubMed]
19. Oefelein MG, Resnick MI. Association of tobacco use with hormone refractory disease and survival of patients with prostate cancer. J Urol 2004;171(6, pt 1):2281-2284. [PubMed]
20. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Urology 2003; 61(2): 365-369. [PubMed]
